A case report of a patient presented with skin ulcer after treatment of lenvatinib
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 차세린 | - |
dc.contributor.author | 정영걸 | - |
dc.contributor.author | 최정완 | - |
dc.contributor.author | 김태형 | - |
dc.contributor.author | 김승영 | - |
dc.contributor.author | 현종진 | - |
dc.contributor.author | 정성우 | - |
dc.contributor.author | 구자설 | - |
dc.contributor.author | 임형준 | - |
dc.contributor.author | 김동우 | - |
dc.date.accessioned | 2021-10-19T00:40:09Z | - |
dc.date.available | 2021-10-19T00:40:09Z | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 2288-8128 | - |
dc.identifier.issn | 2383-5001 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/54534 | - |
dc.description.abstract | A 60-year-old man diagnosed with unresectable hepatocellular carcinoma (HCC) presented to the hospital with pain in the perineal region. He had been taking lenvatinib every day for 2 months after he was diagnosed with HCC with metastases to the lymph node, small bowel mesentery, and retroperitoneal space. Enhanced abdominal computed tomography revealed mild elevation in intensity in the perineal subcutaneous tissue with subcutaneous emphysema. The patient was diagnosed with Common Terminology Criteria for Adverse Events grade 3, skin ulceration of stage IV with full-thickness skin loss and tissue necrosis in the muscular layer. The patient was taken off the medication with prescription of antibiotics, and after 3 weeks, the skin has fully recovered. This is the first report of an HCC patient who presented with a skin ulceration of stage IV after lenvatinib treatment. We recommend stopping the medication immediately and changing to alternative treatments with appropriate supportive care. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한간암학회 | - |
dc.title | A case report of a patient presented with skin ulcer after treatment of lenvatinib | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.17998/jlc.2021.09.20 | - |
dc.identifier.scopusid | 2-s2.0-85160737722 | - |
dc.identifier.bibliographicCitation | 대한간암학회지, v.21, no.2, pp 194 - 198 | - |
dc.citation.title | 대한간암학회지 | - |
dc.citation.volume | 21 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 194 | - |
dc.citation.endPage | 198 | - |
dc.identifier.kciid | ART002759308 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Lenvatinib mesylate | - |
dc.subject.keywordAuthor | Skin ulcer | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Adverse drug event | - |
dc.subject.keywordAuthor | Protein kinase inhibitor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.